Skip to main content
. 2001 Jun;94(6):265–269. doi: 10.1177/014107680109400603

Figure 6.

Figure 6

Effect of VPA-985 administration on urinary AQP2 excretion of heart failure patients according to dose groups. (X axis represents the collection periods. Day - 1 is the baseline observation and day + 1 is the study period. ▪ Baseline; ○ Placebo; • 30 mg; ▵ 75 mg; □ 150 mg; ♦ 250 mg) [Reprinted by permission, from Ref. 20]